Welcome to our dedicated page for SL Science Holding SEC filings (Ticker: SLBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SL Science Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SL Science Holding's regulatory disclosures and financial reporting.
SL Science Holding Ltd (SLBT) filed a Form 4 indicating that Mr. Johnson Lau (Lau Johnson Shun-Pong) resigned as Vice President of Finance effective August 31, 2026. The filing reports no insider transactions, and notes that he is no longer subject to Section 16 reporting requirements.
SL Science Holding Ltd (SLBT) reported a management change. On August 24, 2026, Johnson Lau submitted his resignation as Vice President of Finance to the board of directors. The board accepted his resignation, which is effective August 31, 2026. The company states that Mr. Lau’s resignation was not due to any disagreement regarding its operations, policies, or practices.
SL Science Holding Ltd (SLBT) reported a change in its independent auditor. On August 21, 2026, the company appointed TAAD LLP as its independent registered public accounting firm, effective the same day, replacing ARK Pro CPA & Co, which was dismissed on August 20, 2026. The change was approved by the audit committee after a consideration and evaluation process, and the company states it was not due to any disagreements with ARK over accounting principles, financial statement disclosures, or audit scope or procedures, and that there were no “reportable events” as defined in Item 16F of Form 20-F.
ARK’s prior audit reports on the consolidated financial statements of SL BIO Ltd. for 2024 and 2025 contained no adverse or qualified opinions. ARK’s report on SL Science Holding Ltd’s consolidated financial statements as of December 31, 2025 (from inception on March 18, 2025) likewise contained no adverse or qualified opinions, but did include an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern. The company states it did not consult TAAD on accounting or audit matters before TAAD’s engagement. ARK has been asked to provide a letter to the SEC agreeing or disagreeing with these disclosures, which is filed as an exhibit.
SL Science Holding Limited is registering up to 1,040,000 Ordinary Shares for resale by PIPE investors after a six‑month lock‑up following the June 12, 2026 business combination with Horizon Space Acquisition II Corp. The company will not receive any proceeds from these sales.
The shares comprise 780,000 Ordinary Shares already held by investors and 260,000 Ordinary Shares issuable upon conversion of 780,000 series A preferred shares sold in a $10.00‑per‑Unit PIPE Financing. Ordinary Shares trade on Nasdaq under “SLBT,” last at $2.67 on August 12, 2026.
Chairman William Wang beneficially owns 333,832,129 Ordinary Shares, representing about 59.53% of voting power, making the company a Nasdaq “controlled company” able to rely on reduced board‑independence requirements. SL Science is an emerging growth, foreign private issuer developing pre‑clinical cell and gene therapies, with no FDA‑approved products and extensive scientific, regulatory, financing, concentration, IP, geopolitical and U.S./Taiwan regulatory risks highlighted.
SL Science Holding Limited, a Cayman Islands biomedical company listed on Nasdaq as “SLBT,” has filed to register the resale of up to 1,040,000 Ordinary Shares by existing investors. The shares comprise 780,000 Ordinary Shares already held and 260,000 shares issuable upon conversion of Series A Preferred Shares.
These securities were issued in a June 12, 2026 PIPE Financing in connection with SL Science’s business combination with Horizon Space Acquisition II Corp. The company is not selling shares and will receive no proceeds; sales will occur after a six‑month lock-up expires.
SL Science develops pre‑clinical cell and gene therapies, including Armed‑T and gamma delta T-cell platforms, plus exosome-based products, and has no FDA‑approved products. Chairman William Wang beneficially owns 333,832,129 Ordinary Shares, representing about 59.53% of voting power, qualifying SL Science as a Nasdaq “controlled company.” The prospectus highlights extensive business, financing, concentration, IP, geopolitical, and U.S./Taiwan regulatory risks.
SL Science Holding Limited reported that it has submitted an Orphan Drug Designation request to the U.S. FDA for its Vdelta2+ Gamma Delta T Cells, a GDT cell therapy targeting glioblastoma multiforme (GBM). The FDA’s Office of Orphan Products Development has acknowledged receipt of the request and is reviewing additional product files. The request, filed under Section 526 of the Federal Food, Drug, and Cosmetic Act with designation number DRU-2026-11528, was received on March 30, 2026. SL Science’s GDT platform targets tumor cells independent of MHC presentation, aiming to address GBM, a brain cancer with median survival around 15 months and limited treatment options.
SL Science Holding Ltd discloses that CEO and chairman Ching-Dong Wang, together with SL Link Holding Ltd. and SL Link Co., Ltd., beneficially owns 333,832,129 ordinary shares, representing approximately 59.53% of the company. This stake arose from the business combination between SL BIO Ltd. and Horizon Space Acquisition II Corp. completed on June 12, 2026.
The 333,832,129 ordinary shares include 329,286,823 shares held by SL Link Holding Ltd. and 4,545,306 shares held by SL Link Co., Ltd. The percentages are based on about 560,759,757 ordinary shares issued and outstanding, excluding 260,000 ordinary shares issuable upon conversion of 780,000 preferred shares.
SL Science Holding Ltd director and Chief Executive Officer Wang Ching-Dong filed an initial ownership report showing beneficial ownership of 333,832,129 Ordinary Shares of the company.
These holdings are owned indirectly through SL Link Holding Ltd. and SL Link Co., Ltd., over which Mr. Wang has voting and dispositive power.
SL Science Holding Limited has completed its business combination with Horizon Space Acquisition II Corp., becoming the Nasdaq-listed holding company for SL Bio and focusing on advanced cell and gene therapies. The company is still pre-revenue in therapeutics, with all lead programs in pre-clinical development and no FDA INDs or approvals.
SL Bio reported 2025 net revenue of $2.2 million, down from $3.4 million in 2024, mainly from exosome and plant-extract cosmetics in Taiwan, and a net loss of $3.8 million. Pro forma cash was $9.0 million and total capitalization $9.7 million as of December 31, 2025.
The company’s pipeline centers on CD-19 Armed-T therapy for blood cancers and gamma delta T cell therapies for pancreatic cancer and glioblastoma, supported by long-term licenses from CytoArm and JY BioMed that include up to $4.1 million and $37 million in milestone payments, plus sales-based royalties. Significant additional nonclinical work and FDA interactions are required before clinical trials can begin.